Home › Companies › ALAUNOS THERAPEUTICS INC. › 2023-2024
At ALAUNOS THERAPEUTICS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 64 asset managers reported how they voted in their SEC Form N-PX filings, covering 176 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — ALAUNOS THERAPEUTICS INC.'s filing reports the proposal as approved, with 64% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALAUNOS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ALAUNOS THERAPEUTICS INC.’s Form 8-K, filed June 12, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 6, 2024: 10 items on ALAUNOS THERAPEUTICS INC.’s Form 8-K, filed June 12, 2024: 5 elected · 5 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore ALAUNOS THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ALAUNOS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dale Curtis Hogue, Jr. | 2,312,742 | -- | -- | 657,004 | 5,708,982 | 78% | Elected | — |
| Elect Director: Robert J. Hofmeister | 2,304,704 | -- | -- | 665,042 | 5,708,982 | 78% | Elected | — |
| Elect Director: Robert W. Postma | 1,702,665 | -- | -- | 1,267,081 | 5,708,982 | 57% | Elected | — |
| Elect Director: Jaime Vieser | 2,120,227 | -- | -- | 849,519 | 5,708,982 | 71% | Elected | — |
| Elect Director: Holger Weis | 2,143,828 | -- | -- | 825,918 | 5,708,982 | 72% | Elected | — |
| 2. Ratification of the Selection by the Audit Committee of the Board of Directors of RSM US LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2024 | 7,860,095 | 162,992 | 655,641 | -- | 5,708,982 | 98% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 1,851,846 | 1,032,789 | 85,111 | -- | 5,708,982 | 64% | Approved | — |
| 4. Approval of the Amendment and Restatement of the Certificate of Incorporation to, in the Discretion of the Board, Effect a Reverse Stock Split at a Ratio between 1-for-5 and 1-for-15, Inclusive | 6,057,155 | 2,472,604 | 148,969 | -- | 5,708,982 | 71% | Approved | — |
| 5. Approval of Amendment of the Certificate of Incorporation to Increase the Total Number of Authorized Shares of Common Stock from 34,666,667 Shares to 50,000,000 Shares | 5,961,470 | 2,665,548 | 51,710 | -- | 5,708,982 | 69% | Approved | — |
| 6. Adjournment | 6,410,136 | 2,060,184 | 208,408 | -- | 5,708,982 | 76% | Approved | — |
Source: ALAUNOS THERAPEUTICS INC., Form 8-K, filed with the SEC on June 12, 2024 — read the filing on EDGAR.
Each item below shows how the 64 asset managers that disclosed a ALAUNOS THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ALAUNOS THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: To elect each of the five nominees for director named in the accompanying proxy statement (the "proxy statement") to hold office until the 2025 annual meeting of stockholders and until his or her successor is duly elected and qualified or, if sooner, until his or her earlier death, resignation or removal: Dale Curtis Hogue, Jr.
ALAUNOS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dale Curtis Hogue, Jr.”): 2,312,742 for, 657,004 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected all seven persons listed below as directors, each to serve until the Company's 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 95,873 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 87,765 | 0 | 0 | 0 | For |
| Dimensional | 4,523 | 0 | 0 | 0 | For |
| Fidelity | 2,868 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| John Hancock | 267 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
72% Majority: yes · of votes cast
Description as filed by funds: To elect each of the five nominees for director named in the accompanying proxy statement (the "proxy statement") to hold office until the 2025 annual meeting of stockholders and until his or her successor is duly elected and qualified or, if sooner, until his or her earlier death, resignation or removal: Holger Weis
ALAUNOS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Holger Weis”): 2,143,828 for, 825,918 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected all seven persons listed below as directors, each to serve until the Company's 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 72% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 95,873 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 87,765 | 0 | 0 | 0 | For |
| Dimensional | 4,523 | 0 | 0 | 0 | For |
| Fidelity | 2,868 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| John Hancock | 267 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
71% Majority: yes · of votes cast
Description as filed by funds: To elect each of the five nominees for director named in the accompanying proxy statement (the "proxy statement") to hold office until the 2025 annual meeting of stockholders and until his or her successor is duly elected and qualified or, if sooner, until his or her earlier death, resignation or removal: Jaime Vieser
ALAUNOS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jaime Vieser”): 2,120,227 for, 849,519 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected all seven persons listed below as directors, each to serve until the Company's 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 95,873 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 87,765 | 0 | 0 | 0 | For |
| Dimensional | 4,523 | 0 | 0 | 0 | For |
| Fidelity | 2,868 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| John Hancock | 267 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: To elect each of the five nominees for director named in the accompanying proxy statement (the "proxy statement") to hold office until the 2025 annual meeting of stockholders and until his or her successor is duly elected and qualified or, if sooner, until his or her earlier death, resignation or removal: Robert J. Hofmeister
ALAUNOS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Robert J. Hofmeister”): 2,304,704 for, 665,042 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected all seven persons listed below as directors, each to serve until the Company's 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 95,873 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 87,765 | 0 | 0 | 0 | For |
| Dimensional | 4,523 | 0 | 0 | 0 | For |
| Fidelity | 2,868 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| John Hancock | 267 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
57% Majority: yes · of votes cast
Description as filed by funds: To elect each of the five nominees for director named in the accompanying proxy statement (the "proxy statement") to hold office until the 2025 annual meeting of stockholders and until his or her successor is duly elected and qualified or, if sooner, until his or her earlier death, resignation or removal: Robert W. Postma
ALAUNOS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Robert W. Postma”): 1,702,665 for, 1,267,081 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected all seven persons listed below as directors, each to serve until the Company's 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 57% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 91,083 for, 4,523 withheld, 267 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 87,765 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 4,523 | Withhold |
| Fidelity | 2,868 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 267 | 0 | Abstain |
Combines 3 wordings of this item as funds reported it.
69% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's Charter, in substantially the form attached to the proxy statement as Annex B, to, at the discretion of the Board, increase the number of shares of common stock authorized for issuance thereunder from 34,666,667 shares to 50,000,000 shares.
ALAUNOS THERAPEUTICS INC.’s own tally for this item (“5. Approval of Amendment of the Certificate of Incorporation to Increase the Total Number of Authorized Shares of Common Stock from 34,666,667 Shares to 50,000,000 Shares”): 5,961,470 for, 2,665,548 against — passed, per its Form 8-K filed June 12, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 5 - Approval of Amendment of the Certificate of Incorporation to Increase the Total Number of Authorized Shares of Common Stock from 34,666,667 Shares to 50,000,000 Shares The Company's stockholders approved Proposal 5.”
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 95,873 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 87,765 | 0 | 0 | 0 | For |
| Dimensional | 4,523 | 0 | 0 | 0 | For |
| Fidelity | 2,868 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| John Hancock | 267 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
71% Approved · of votes cast
Description as filed by funds: To approve the amendment and restatement of the Company's second amended and restated certificate of incorporation, as amended (our "Charter"), in substantially the form attached to the proxy statement as Annex A, to, at the discretion of the Board, effect a reverse stock split with respect to the Company's issued and outstanding common stock, par value $0.001 per share, including stock held by the Company as treasury shares, at a reverse stock split ratio of 1-for-5 to 1-for-15, inclusive.
ALAUNOS THERAPEUTICS INC.’s own tally for this item (“4. Approval of the Amendment and Restatement of the Certificate of Incorporation to, in the Discretion of the Board, Effect a Reverse Stock Split at a Ratio between 1-for-5 and 1-for-15, Inclusive”): 6,057,155 for, 2,472,604 against — passed, per its Form 8-K filed June 12, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4 - Approval of the Amendment and Restatement of the Certificate of Incorporation to, in the Discretion of the Board, Effect a Reverse Stock Split at a Ratio between 1-for-5 and 1-for-15, Inclusive The Company's stockholders approved Proposal 4.”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 95,873 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 87,765 | 0 | 0 | 0 | For |
| Dimensional | 4,523 | 0 | 0 | 0 | For |
| Fidelity | 2,868 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| John Hancock | 267 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
100% of fund votes cast · no official result
Description as filed by funds: To approve a proposal to adjourn the Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal 5 and Proposal 6 ("Proposal 6").
The 5 asset managers below reported 95,873 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 87,765 | 0 | 0 | 0 | For |
| Dimensional | 4,523 | 0 | 0 | 0 | For |
| Fidelity | 2,868 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| John Hancock | 267 | 0 | 0 | 0 | For |
Combines 6 wordings of this item as funds reported it.
64% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.
ALAUNOS THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 1,851,846 for, 1,032,789 against — passed, per its Form 8-K filed June 12, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3.”
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 87,765 | 0 | 0 | 0 | For |
| Dimensional | 0 | 4,523 | 0 | 0 | Against |
| Fidelity | 2,868 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| John Hancock | 267 | 0 | 0 | 0 | For |
Fund voting reports, all 5 managers: 91,350 for, 4,523 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GARDNER RUSSO & QUINN LLC | 70,624 | 0 | 0 | 0 | For |
| BlackRock | 65,445 | 0 | 0 | 0 | For |
| COMMERCE BANK | 29,132 | 0 | 0 | 0 | For |
| State Street | 21,265 | 0 | 0 | 0 | For |
| CIBC Private Wealth Group LLC | 14,666 | 0 | 0 | 0 | For |
| Northern Trust | 12,646 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 7,822 | 0 | 0 | 0 | For |
| BLAIR WILLIAM & CO/IL | 6,248 | 0 | 0 | 0 | For |
| Vanguard | 5,011 | 0 | 0 | 0 | For |
| Janney Montgomery Scott LLC | 3,453 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,285 | 0 | 0 | 0 | For |
| Summit Trail Advisors, LLC | 1,849 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 1,419 | 0 | 0 | 0 | For |
| BANK OF MONTREAL /CAN/ | 1,336 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 1,248 | 0 | 0 | 0 | For |
| Citadel | 1,028 | 0 | 0 | 0 | For |
| Chicago Partners Investment Group LLC | 934 | 0 | 0 | 0 | For |
| SCS Capital Management LLC | 677 | 0 | 0 | 0 | For |
| BOKF, NA | 666 | 0 | 0 | 0 | For |
| Freestone Capital Holdings, LLC | 666 | 0 | 0 | 0 | For |
| ROCKEFELLER FINANCIAL LLC | 589 | 0 | 0 | 0 | For |
| Family Management Corp | 508 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| ENVESTNET ASSET MANAGEMENT INC | 385 | 0 | 0 | 0 | For |
| Rodgers Brothers Inc. | 0 | 332 | 0 | 0 | Against |
Institutional-manager reports, all 62 managers: 254,030 for, 353 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: To ratify the selection of RSM US LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024 by the audit committee (the "audit committee") of the board of directors of the Company (the "Board").
ALAUNOS THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the Selection by the Audit Committee of the Board of Directors of RSM US LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2024”): 7,860,095 for, 162,992 against — passed, per its Form 8-K filed June 12, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of the Selection by the Audit Committee of the Board of Directors of RSM US LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2024 The Company's stockholders approved Proposal 2.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 95,873 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 87,765 | 0 | 0 | 0 | For |
| Dimensional | 4,523 | 0 | 0 | 0 | For |
| Fidelity | 2,868 | 0 | 0 | 0 | For |
| Charles Schwab | 450 | 0 | 0 | 0 | For |
| John Hancock | 267 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 16,012,522 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 0.55% |
| 2 | Dimensional | 0.03% |
| 3 | Fidelity | 0.02% |
| 4 | Charles Schwab | <0.01% |
| 5 | John Hancock | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GARDNER RUSSO & QUINN LLC | 0.44% |
| 2 | BlackRock | 0.41% |
| 3 | COMMERCE BANK | 0.18% |
| 4 | State Street | 0.13% |
| 5 | CIBC Private Wealth Group LLC | 0.09% |
| 6 | Northern Trust | 0.08% |
| 7 | STIFEL NICOLAUS & CO INC \MO\ | 0.05% |
| 8 | BLAIR WILLIAM & CO/IL | 0.04% |
| 9 | Vanguard | 0.03% |
| 10 | Janney Montgomery Scott LLC | 0.02% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| S | 24.99% | 13G |
| Level One Parties | 10.07% | DEF14A |
| MSD Credit Opportunity Master Fund, L.P. | 9.46% | DEF14A |
| Robert W. Postma | 2.78% | DEF14A |
| Jaime Vieser | 1.43% | DEF14A |
| PMGC CAPITAL LLC | 0.52% | 13D |
| Kevin S. Boyle, Sr. | 0.33% | DEF14A |
| Dale Curtis Hogue, Jr. | 0.33% | DEF14A |
| Holger Weis | 0.22% | DEF14A |
| BlackRock | 0.13% | 13F |
Percentages above are of 16,012,522 shares outstanding, as reported by ALAUNOS THERAPEUTICS INC. on its Form 10-Q dated May 12, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALAUNOS THERAPEUTICS INC.’s 10-Q dated May 12, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ALAUNOS THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).
proxyvotesnow.com, “ALAUNOS THERAPEUTICS (TCRT) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/alaunos-therapeutics-inc/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.